Half-life of somatostatin-like immunoreactivity in canine plasma. 1979

V Schusdziarra, and V Harris, and R H Unger

Previous estimates of the half-life of synthetic somatostatin have been based upon the disappearance rate of 125I-labeled Tyr1-somatostatin. In the present study, the half-life of infused synthetic somatostatin was determined by RIA and compared with the duration of its suppressive action upon plasma insulin and glucagon. After the end of a 2-h infusion of somatostatin (500 ng/min), the radioimmunologically measured half-life was 1.82 min. The reappearance half-times for insulin and glucagon were 1.4 and 6.7 min, respectively. These data show that calculations of the half-life of somatostatin-like immunoreactivity in plasma may differ from estimates based on the duration of its biological activities, which may differ from one another.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

V Schusdziarra, and V Harris, and R H Unger
October 1978, FEBS letters,
V Schusdziarra, and V Harris, and R H Unger
June 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
V Schusdziarra, and V Harris, and R H Unger
January 1998, Journal of endocrinological investigation,
V Schusdziarra, and V Harris, and R H Unger
December 1978, The Journal of clinical investigation,
V Schusdziarra, and V Harris, and R H Unger
March 1982, Diabete & metabolisme,
V Schusdziarra, and V Harris, and R H Unger
June 1984, Bollettino della Societa italiana di biologia sperimentale,
V Schusdziarra, and V Harris, and R H Unger
May 1979, Clinical endocrinology,
V Schusdziarra, and V Harris, and R H Unger
July 1985, The Journal of clinical endocrinology and metabolism,
V Schusdziarra, and V Harris, and R H Unger
July 1981, The Journal of clinical investigation,
Copied contents to your clipboard!